Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

US Patent 10456413 · Granted Oct 29, 2019

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Base-modified cytidine nucleotides for leukemia therapy2025
Base-modified cytidine nucleotides for leukemia therapy2025
Base-modified cytidine nucleotides for leukemia therapy2025
Methods for treating liver cancers using an orally administered dioxolane nucleo2025
Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides2025
Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides2025
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2022
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination thera2021
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination thera2021
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination thera2021